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This case suggests the possible presence of somatostatin recep-etter  to  the  Editor
 case of facial nerve schwannoma with positive
ctreotide scintigraphy
n cas de schwannome du nerf facial avec scintigraphie à l’octréotide
ositive
A 72-year-old woman with a 10-year history of grade VI left
eripheral facial paralysis according to House Brackmann’s clas-
iﬁcation, not investigated by imaging at the time of onset, was
eferred following the discovery of a tumour obstructing the exter-
al auditory canal, without earache or otorrhoea. She had initially
xperienced vertigo, hypoacusis and pulsatile tinnitus gradually
eteriorating over a period of about two years. She had no other
otable personal or family history.
Pure-tone audiometry revealed mixed hearing loss of 70 dB in
he left ear with a speech reception threshold of 67 dB.
CT scan of the ear showed opaciﬁcation of the tympanum
nd external auditory canal. MRI  showed a strongly gadolinium-
nhanced mass measuring 31 × 46 mm,  in close contact with the
ome of the jugular bulb (Fig. 1). The radiologist concluded on a
ossible tympanic glomus paraganglioma. Octreotide scintigraphy
emonstrated uptake by the lesion, strongly supporting the suspi-
ion of paraganglioma (Fig. 2). No uptake was observed on MIBG
cintigraphy. The absence of abnormal contrast enhancement on
rteriography was an argument against paraganglioma. Surgical
xploration revealed a tumour of the second and third parts of the
acial nerve, corresponding to a schwannoma.Schwannomas of the facial nerve are rare tumours, as fewer than
00 cases have been reported in the literature [1]. They have an
xtremely variable clinical presentation, as they can involve any
Fig. 1. Non-enhanced and contrast-enhanced MRI  T1-weighted sequence of the 
http://dx.doi.org/10.1016/j.anorl.2014.06.004
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.segment of the nerve [1]. They originate from the labyrinthine seg-
ment in 43.5% of cases, the tympanic segment in 42.8% of cases and
the mastoid segment in 36.7% of cases [1]. Multisegment lesions
are common [2]. The most common clinical sign is progressive
peripheral facial paralysis (73% of cases) [2]. Schwannomas pro-
trude through the external auditory canal in only 11% of cases
[2].
Tympanic paragangliomas are neuroendocrine tumours, usu-
ally benign, arising from paraganglionic tissue [3] derived from
the neural crest. Tympanic paragangliomas generally arise in the
promontory along the tympanic nerve. They usually present as a
pulsatile raspberry tumour, raising the tympanic membrane, and
are accompanied by otological (hearing loss, tinnitus) and neuro-
logical signs (glossopharyngeal, vagus, and accessory nerve lesions,
and late peripheral facial paralysis).
111Indium-labelled octreotide scintigraphy has a sensitivity of
more than 95% for the diagnosis of paraganglioma [3]. Octreotide is
a somatostatin analogue [4], which binds to somatostatin surface
receptors. Somatostatin is essentially expressed by neuroendocrine
tumours, Hodgkin’s lymphomas, as well as most meningiomas and
astrocytomas [4]. The original case of schwannoma reported here
showed intense octreotide uptake, which has never previously
been reported in the literature.
Octreotide scintigraphy has even been used in some studies for
the differential diagnosis between meningioma and schwannoma
[5].lesion showing homogeneous contrast enhancement at the arterial phase.
tors on the surface of some schwannomas and also highlights the
fact that no complementary investigation is able to clearly establish
a deﬁnitive preoperative diagnosis.
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[Fig. 2. Octreotide scan showing
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